Clinical trials that utilize BCL‐2 inhibitors are becoming more and more prevalent and could potentially show exciting results as an efficient treatment for many different forms of blood cancer, such as chronic lymphocytic leukemia, acute myeloid leukemia and Non‐Hodgkin's lymphoma.38 Here, BCL2 is linked to hematopoietic and lymphoid system neoplasm.